Recently, the combination of atezolizumab, a PD-L1 (programmed death-ligand 1) inhibitor, and bevacizumab, a VEGF inhibitor, has been shown to improve overall survival when compared to sorafenib, the previous standard-of-care first-line therapy for advanced HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.